Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthieu Boucher

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Journal of Affective Disorders|August 15, 2022
Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: A post hoc analysis of four clinical studiesMartin A Katzman, François Therrien, Erin M MacKenzie, et al.
Menopause (New York, N.Y.)|December 24, 2015
The effect of conjugated estrogens/bazedoxifene therapy on body weight of postmenopausal women: pooled analysis of five randomized, placebo-controlled trialsDenise Black, Michael Messig, Ching-Ray Yu, et al.
Journal of Psychiatry & Neuroscience : JPN|January 25, 2007
Vulnerability for apoptosis in the limbic system after myocardial infarction in rats: a possible model for human postinfarct major depressionBoubacar Pasto Wann, Thierno Madjou Bah, Matthieu Boucher, et al.
International Clinical Psychopharmacology|February 20, 2016
An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorderJosé L Carrasco, Susan G Kornstein, Roger S McIntyre, et al.
Journal of Clinical Psychopharmacology|August 18, 2017
Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive DisorderMartin A Katzman, Andrew A Nierenberg, Dalia B Wajsbrot, et al.
International Clinical Psychopharmacology|June 10, 2017
Long-term function and psychosocial outcomes with venlafaxine extended release 75-225 mg/day versus placebo in the PREVENT studyKoichiro Watanabe, Michael E Thase, Toshiaki Kikuchi, et al.
Clinical and Translational Science|May 7, 2010
Simultaneous administration of insulin-like growth factor-1 and darbepoetin alfa protects the rat myocardium against myocardial infarction and enhances angiogenesisMatthieu Boucher, Stéphanie Pesant, Yong Hong Lei, et al.
Current Medical Research and Opinion|March 12, 2015
Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysisMichael E Thase, Rana Fayyad, Ru-Fong J Cheng, et al.
Current Medical Research and Opinion|August 3, 2019
Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in the United States: a real-world studyRoger S McIntyre, Rita Prieto, Patricia Schepman, et al.
International Clinical Psychopharmacology|August 1, 2015
Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysisAnita H Clayton, Eunhee Hwang, Susan G Kornstein, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Journal of Affective Disorders|August 15, 2022
Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: A post hoc analysis of four clinical studiesMartin A Katzman, François Therrien, Erin M MacKenzie, et al.
Menopause (New York, N.Y.)|December 24, 2015
The effect of conjugated estrogens/bazedoxifene therapy on body weight of postmenopausal women: pooled analysis of five randomized, placebo-controlled trialsDenise Black, Michael Messig, Ching-Ray Yu, et al.
Journal of Psychiatry & Neuroscience : JPN|January 25, 2007
Vulnerability for apoptosis in the limbic system after myocardial infarction in rats: a possible model for human postinfarct major depressionBoubacar Pasto Wann, Thierno Madjou Bah, Matthieu Boucher, et al.
International Clinical Psychopharmacology|February 20, 2016
An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorderJosé L Carrasco, Susan G Kornstein, Roger S McIntyre, et al.
Journal of Clinical Psychopharmacology|August 18, 2017
Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive DisorderMartin A Katzman, Andrew A Nierenberg, Dalia B Wajsbrot, et al.
International Clinical Psychopharmacology|June 10, 2017
Long-term function and psychosocial outcomes with venlafaxine extended release 75-225 mg/day versus placebo in the PREVENT studyKoichiro Watanabe, Michael E Thase, Toshiaki Kikuchi, et al.
Clinical and Translational Science|May 7, 2010
Simultaneous administration of insulin-like growth factor-1 and darbepoetin alfa protects the rat myocardium against myocardial infarction and enhances angiogenesisMatthieu Boucher, Stéphanie Pesant, Yong Hong Lei, et al.
Current Medical Research and Opinion|March 12, 2015
Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysisMichael E Thase, Rana Fayyad, Ru-Fong J Cheng, et al.
Current Medical Research and Opinion|August 3, 2019
Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in the United States: a real-world studyRoger S McIntyre, Rita Prieto, Patricia Schepman, et al.
International Clinical Psychopharmacology|August 1, 2015
Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysisAnita H Clayton, Eunhee Hwang, Susan G Kornstein, et al.
Pageof 5